Adjuvant systemic therapy of breast cancer
The first procedure in primary breast cancer is usually the surgical excision of the tumor. However, a medical therapy is necessary in almost all patients to treat the systemic component of the disease. Which medical approach is recommended depends on the biology of the tumor itself. Endocrine-respo...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 3, 2011
|
| In: |
Breast care
Year: 2011, Jahrgang: 6, Heft: 3, Pages: 179-183 |
| ISSN: | 1661-3805 |
| DOI: | 10.1159/000329336 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000329336 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/329336 
|
| Verfasserangaben: | Florian Schuetz (Department of Gynecology and Obstetrics, Heidelberg University Hospital, Germany) |
| Zusammenfassung: | The first procedure in primary breast cancer is usually the surgical excision of the tumor. However, a medical therapy is necessary in almost all patients to treat the systemic component of the disease. Which medical approach is recommended depends on the biology of the tumor itself. Endocrine-responsive tumors must be treated by an endocrine therapy according to their menopausal status. In HER2/neu-overexpressing tumors, the monoclonal antibody trastuzumab is part of the standard treatment in combination with chemotherapy. Hormone receptor-negative and non-HER2/neu-overexpressing tumors as well as endocrine-responsive tumors with a high proliferation index or additional risk factors must be treated with chemotherapy as well. This review article gives further information about the available agents and schedules. |
|---|---|
| Beschreibung: | Gesehen am 27.10.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1661-3805 |
| DOI: | 10.1159/000329336 |